Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 293-304 , April 2007

In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer

  • Emmanuelle N. Sabbah

      Affiliations

    • M.A.T., Génocampus 1, 5 rue Henri Desbrvères, 91030 Evry cedex, France
    • Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, EC1A 7BE London, United Kingdom
    • Corresponding Author InformationCorresponding author. Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, London EC1A 7BE, United Kingdom. Tel.: + 44 0 207 601 71 51; fax +44 0 207 601 71 43.
    • ,
  • Jean Kadouche

      Affiliations

    • M.A.T., Génocampus 1, 5 rue Henri Desbrvères, 91030 Evry cedex, France
    • ,
  • David Ellison

      Affiliations

    • Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, EC1A 7BE London, United Kingdom
    • ,
  • Ciara Finucane

      Affiliations

    • Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, EC1A 7BE London, United Kingdom
    • ,
  • Didier Decaudin

      Affiliations

    • Institut Curie, Clinical Haematology, 75005 Paris, France
    • ,
  • Stephen J. Mather

      Affiliations

    • Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, EC1A 7BE London, United Kingdom

Received 24 November 2006 ,Revised 26 December 2006 ,Accepted 5 January 2007.

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30
  2. Newman EA, Simeone DM, Mulholland MW. Adjuvant treatment strategies for pancreatic cancer. J Gastrointest Surg. 2006;10(6):916–926
  3. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73(3):485–492
  4. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol. 2006;58(3):231–241
  5. Kaufmann LW, Vaillant JC, van Gulik TM, van Royen EA, Parc R, Obertop H. Efficacy of monoclonal antibody 131I-B72.3 immunoscintigraphy of pancreatic adenocarcinoma xenografts in nude mice. Eur J Surg. 1999;165(7):659–664
  6. Otsuji E, Matsumura H, Okamoto K, Toma A, Kuriu Y, Ichikawa D, et al. Application of 99mTc labeled chimeric Fab fragments of monoclonal antibody A7 for immunoscintigraphy of pancreatic carcinoma. J Surg Oncol. 2003;84(3):160–165
  7. Worlock AJ, Zalutsky MR, Metzgar RS. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res. 1990;50(22):7246–7251
  8. Yao CZ, Poston GJ, Ishizuka J, Townsend CM, Thompson JC. Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2. Pancreas. 1993;8(3):289–294
  9. Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang CH, Modrak DE, et al. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res. 2004;10(10):3552–3561
  10. Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004;109(4):618–626
  11. Panicot-Dubois L, Aubert M, Franceschi C, Mas E, Silvy F, Crotte C, et al. Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts. Neoplasia. 2004;6(6):713–724
  12. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006;12(7 Pt 1):2197–2207
  13. Friess H, Gassmann M, Buchler MW. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Int J Pancreatol. 1997;21(1):43–52
  14. Azria D, Larbouret C, Garambois V, Kramar A, Martineau P, Robert B, et al. Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer. Br J Cancer. 2003;89(10):1987–1994
  15. Guner G, Kirkali G, Yenisey C, Tore IR. Cytosol and serum ferritin in breast carcinoma. Cancer Lett. 1992;67(2–3):103–112
  16. Weinstein RE, Bond BH, Silberberg BK, Vaughn CB, Subbaiah P, Pieper DR. Tissue ferritin concentration and prognosis in carcinoma of the breast. Breast Cancer Res Treat. 1989;14(3):349–353
  17. Eshhar Z, Order SE, Katz DH. Ferritin, a Hodgkin's disease associated antigen. Proc Natl Acad Sci U S A. 1974;71(10):3956–3960
  18. Drysdale JW, Adelman TG, Arosio P, Casareale D, Fitzpatrick P, Harzard JT, et al. Human isoferritins in normal and disease states. Semin Hematol. 1977;14(1):71–88
  19. Marcus DM, Zinberg N. Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoadsorbents. Arch Biochem Biophys. 1974;162(2):493–501
  20. Vriesendorp HM, Quadri SM. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease. Cancer Biother Radiopharm. 2000;15(5):431–445
  21. Vriesendorp HM, Morton JD, Quadri SM. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res. 1995;55(23 Suppl):5888s–5892s
  22. Klein JL, Nguyen TH, Laroque P, Kopher KA, Williams JR, Wessels BW, et al. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma. Cancer Res. 1989;49(22):6383–6389
  23. Kadouche J, Darne C, Ketels F, Pouletty P, Crevat D, Kalil J, et al. Analysis of various isoferritins with monoclonal antibodies. C R Seances Acad Sci III. 1982;295(6):443–448
  24. Cooper M, Sabbah E, Mather SJ. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes. Nature Protocols. 2006;1:314–317
  25. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142(1):68–78
  26. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72(1):77–89
  27. Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am J Pathol. 1982;106(2):250–260
  28. Goldstein D, Nassar T, Lambert G, Kadouche J, Benita S. The design and evaluation of a novel targeted drug delivery system using cationic emulsion-antibody conjugates. J Control Release. 2005;108(2–3):418–432
  29. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24(4):539–567
  30. Harrison A, Walker CA, Parker D, Jankowski KJ, Cox JP, Craig AS, et al. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Int J Rad Appl Instrum B. 1991;18(5):469–476
  31. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1989;30(5):672–682
  32. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35(5):882–889
  33. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 1997;5(10):1925–1934
  34. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137–1146
  35. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001;7(10):3186–3192
  36. Vriesendorp HM, Quadri SM, Andersson BS, Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol. 1996;24(10):1183–1190
  37. Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003;9:3929S–3937S
  38. Von Hoff DD. What's new in pancreatic cancer treatment pipeline?. Best Pract Res Clin Gastroenterol. 2006;20(2):315–3126
  39. Cascinu S, Verdecchia L, Valeri N, Berardi R, Scartozzi M. New target therapies in advanced pancreatic cancer. Ann Oncol. 2006;17(Suppl 5):v148–v152
  40. Kleespies A, Jauch KW, Bruns CJ. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?. Drug Resist Updat. 2006;9(1–2):1–18

PII: S0969-8051(07)00011-X

doi: 10.1016/j.nucmedbio.2007.01.004

Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 293-304 , April 2007

Article Tools

* Image Usage & Resolution